fda compounding glp-1 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our 🚨 FDA Moves to Permanently

Your APP will review your medical and surgical history with you

This is a known concern with GLP-1 medications, and tirzepatide and bone loss is an active area of research

and she had a full-term pregnancy at 25 years of age, regular

The 5- and 10-year survival probabilities in this matched obesity cohort favored GLP-1 receptor agonist users, and the authors interpreted these data as suggesting a potentially meaningful long-term association between GLP-1 receptor agonist exposure and improved outcomes in this group

How is Saxenda different from Wegovy

Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation